INNOVATE Business Summary

INNOVATE Corp. (VATE) operates as a diversified holding company that generates revenue through a mix of project-based construction fees, medical device sales, and broadcasting distribution rights. The company’s primary business segments include Infrastructure, anchored by DBM Global Inc., which provides integrated structural steel and industrial construction services; Life Sciences, via Pansend Life Sciences, which develops healthcare technologies like MediBeacon’s kidney function monitoring and R2 Technologies’ aesthetic devices; and Spectrum, which manages a massive portfolio of over-the-air broadcast stations through HC2 Broadcasting. As of early 2026, the company is actively pursuing a strategic pivot, exploring the divestiture of its Life Sciences assets and alternatives for its broadcasting arm to address a high-leverage capital structure. INNOVATE competes with industrial and engineering giants such as Fluor Corporation, MasTec, and Steel Partners Holdings, positioning itself as a specialized small-cap player focused on niche infrastructure and high-growth technology verticals. Originally founded in 1994 as Primus Telecommunications and later known as HC2 Holdings, the company is currently led by Interim CEO Paul K. Voigt, who brings extensive capital markets experience from his tenure at Lancer Capital and Jefferies. The executive team includes Chief Financial Officer Michael J. Sena, who oversees the firm’s complex debt restructuring and financial reporting, and Chief Operating Officer Suzi Herbst. The company’s strategic direction is heavily influenced by Chairman Avram “Avie” Glazer, the principal of Lancer Capital and Executive Co-Chairman of Manchester United, who has significantly increased his stake in recent years. Other key board members include veteran tax professional Brian Goldstein and innovation expert Amy Wilkinson. Notable institutional support remains anchored by Lancer Capital, Jefferies Financial Group, and major passive investors like Vanguard and BlackRock.